ZYME – USA News Group

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

Biopharma, Inc., CTMX, CytomX Therapeutics, CytomX Therapeutics, Inc., GT Biopharma, Inc., GTBP, NRIX, Nurix Therapeutics, Nurix Therapeutics, Inc., RSS, Xencor, Xencor, Inc., XNCR, ZYME, Zymeworks, Zymeworks Inc. July 06, 2026 American News Group

GT Biopharma, Inc. reported on June 1, 2026 that it has integrated AI-based tools into the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, with the expectation that resulting efficiency gains will advance multiple new development candidates into pre-IND development in 2027.

General Disclaimer & Disclosure. USA News Group publishes sponsored and paid-for editorial content produced in the form of digital media distribution. This material is prepared and issued by USA News Group on behalf of Market Equities Limited (“Market Equities” or “MEL”), and is provided strictly for general informational and investor-awareness purposes. Nothing published by USA News Group is, or should be construed as, investment, financial, tax, accounting, or legal advice, nor as an offer, recommendation, or solicitation to buy, sell, or hold any security.
Compensation. Market Equities is engaged in the business of marketing and advertising companies for monetary compensation. Unless otherwise expressly stated in an article-specific disclaimer, Market Equities has received, or expects to receive, compensation for the production and distribution of content appearing on this website, either directly from a profiled issuer or from a third-party engaging party such as an investor-relations firm or marketing agency. The specific nature, source, and amount of compensation is set out in the disclaimer accompanying each individual article.
Ownership & Positions. Market Equities Limited, its related and affiliated entities, and their respective owners, directors, officers, employees, and affiliates may hold, acquire, or dispose of shares or other securities of the companies profiled on this website. Any such positions, and the manner in which they were acquired, are disclosed in the applicable article-specific disclaimer. These parties reserve the right to purchase or sell such securities at any time, with or without notice, which may affect the price of those securities.
No Guarantee of Accuracy. Information published on this website is obtained from sources believed to be reliable, including public disclosures, regulatory filings, and materials supplied by profiled issuers. However, neither USA News Group nor Market Equities independently verifies all such information, and neither guarantees its accuracy, completeness, or timeliness. All content is provided “as is,” and neither party assumes any obligation to update it.
Forward-Looking Statements. Content on this website may contain forward-looking statements within the meaning of applicable securities legislation. Such statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements.
Reader Responsibility. Investing in securities, particularly small-capitalization and micro-cap issuers, carries a high degree of risk and may result in the loss of some or all of an investment. Readers should not make any investment decision based on the content of this website. Before acting on any information, readers should conduct their own due diligence and consult a licensed financial, legal, or tax professional. By accessing USA News Group, you acknowledge and agree to the terms of this disclaimer.